TX-PLANVIEW
Planview, the leading platform for connected work from portfolio planning to delivery, announced today the release of the 2023 Project to Product State of the Industry Report. The landmark report, which benchmarks organizational shifts required to support and accelerate digital innovation, found that many companies are unable to complete transformational work due to immature operating models and management systems.
Among the key findings in Planview’s report, only 8% of organizations have successfully operationalized their project to product transformation. The low success rate contradicts the previously optimistic outlook from a 2018 report claiming that 85% of executives said they had either adopted or had plans to adopt a product-centric model, motivated by a desire to improve speed to market and agility and to support the move to digital business. Five years later, the report’s data underscores the complexity of this multi-year process and its required buy-in and commitment across all levels of the organization.
“In boardrooms across the globe, executives are being mandated to prioritize technology investments that ensure their companies transform and emerge from the current downturn stronger. While some enterprise initiatives are managed as projects, a product-based operating model holds the key to increased efficiency, better customer outcomes, and profitable growth for digital portfolios,” said Dr. Mik Kersten, CTO, Planview and author of the bestselling book Project to Product: How to Survive and Thrive in the Age of Digital Disruption with the Flow Framework. “The consequences of slow delivery and technical debt can be seen in very public profit losses and system-wide malfunctions. While there are no shortcuts, there is a roadmap of best practices that accelerates the transition, which the report outlines.”
The report from Planview, which uniquely combines survey data from 326 respondents with systems data from 3,600+ software development value streams in 34 of the world’s leading enterprises, reveals that five years into the shift from project to product:
- 92% of businesses do not have the foundation for a product-oriented model, causing their digital transformation efforts to fail
- Business leaders believe their IT and software development teams, in charge of transformation efforts, can deliver 10x more than their actual capacity, leading to team burnout
- 40% of digital innovation work from IT and engineering teams are wasted due to shifting priorities at the C-level
- Only 8% of what’s planned by IT and software development teams gets delivered, inefficiency that can no longer be ignored given today’s cost and performance pressures
Given the criticality of this shift for the future success of traditional companies versus early adopters, this report outlines the critical steps needed to accelerate this transition: a partnership between executives and senior product and development leadership to do the following:
- Benchmark their progress versus their competitors
- Understand and implement best practices to shorten the time it takes to capture the ROI of transformation efforts
- Identify the organizational attributes that increase the likelihood of operationalizing the product model by learning which efforts to prioritize
“This report is the first of its kind to benchmark the success of enterprise transformation initiatives based on the dimensions first outlined in Dr. Mik Kersten’s seminal book five years ago,” said Jonathan Webster, Managing Director and Partner, Boston Consulting Group. “While the research shows that the majority of organizations are still in the early stages of their product-model journey, the report offers the blueprint for leaders to accelerate the remainder of the effort.”
This report follows Planview’s acquisition of Tasktop last year. Planview Tasktop solutions implement the popular Flow Framework® created by Dr. Mik Kersten, former Tasktop Founder & CEO.
Go here to download the full report from Planview: The 2023 Project to Product State of the Industry Report
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
Report Methodology
-
Survey data was collected from April – December 2022
- It was analyzed using regression analysis to check for interdependence and correlation of responses with the stage organizations have reached in the shift. (The Firth Logistic Regression method was used, which is well-tested for data sets of this size.)
- 326 individuals from 253 unique companies
- Top 4 industries: Financial Services, Healthcare, Technology, Energy/Utilities
- Geographies: 53% North America, 28% Europe, 15% APAC, 3% South America, 1% Africa
- Job Levels: 67% Manager, 14% Director, 10% Executive, 9% Consultant
- Functional Areas: 50% Engineering/IT, 13% PMO, 10% Consultant, 6% Product Management, 4% Transformation, 10% Other (various functions)
- Anonymized systems data was aggregated from over 3,600 value streams from 34 organizations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 11:12:00 CEST | Press release
This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP)The study is being conducted across 44 centers in the European Union, the United Kingdom, and the United StatesThe study reinforces Ferrer’s commitment to researching and developing transformative therapeutic solutions for people with rare neurological diseases Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 10:51:00 CEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 10:00:00 CEST | Press release
Investment in European infrastructure strengthens Impartner’s EMEA operations and commitment to data security and regional growth Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azu
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 10:00:00 CEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
INNIO Secures Largest Order in Company History with VoltaGrid Delivering Power Generation for One of the World’s Largest Data Centers21.10.2025 09:01:00 CEST | Press release
INNIO to supply 2.3 gigawatts (GW) of power infrastructure, comprising 92 power packs of 25 megawatts (MW) each. Partnership with VoltaGrid drives the expansion of AI data centers through fast, flexible, and sustainable energy solutions. Collaboration enables VoltaGrid to seamlessly combine its power pack units with its large-scale portable data center power made up of INNIO’s units. INNIO Group today announced the largest order by power delivery in its history: a groundbreaking 2.3 GW power infrastructure project featuring 92 power packs, each delivering 25 MW of output. The initiative with VoltaGrid strengthens INNIO’s position as a key energy solutions provider for the rapidly expanding U.S. data center sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021503080/en/ INNIO Secures Largest Order in Company History (c) INNIO “This landmark order underscores the strength of INNIO’s technology and our ability to power
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom